Point72 Asset Management L.P. Takes $1.40 Million Position in Regulus Therapeutics Inc. (NASDAQ:RGLS)

Point72 Asset Management L.P. purchased a new stake in Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 893,762 shares of the biopharmaceutical company's stock, valued at approximately $1,403,000. Point72 Asset Management L.P. owned about 1.36% of Regulus Therapeutics as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in RGLS. Creative Planning bought a new position in shares of Regulus Therapeutics in the third quarter worth about $26,000. SG Americas Securities LLC acquired a new stake in shares of Regulus Therapeutics in the third quarter valued at approximately $33,000. Rhumbline Advisers bought a new position in Regulus Therapeutics in the 2nd quarter worth approximately $136,000. Tyche Wealth Partners LLC lifted its holdings in Regulus Therapeutics by 920.6% during the 3rd quarter. Tyche Wealth Partners LLC now owns 106,089 shares of the biopharmaceutical company's stock worth $167,000 after buying an additional 95,694 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its position in Regulus Therapeutics by 56.4% in the 2nd quarter. Renaissance Technologies LLC now owns 118,100 shares of the biopharmaceutical company's stock valued at $211,000 after buying an additional 42,600 shares during the last quarter. Institutional investors and hedge funds own 92.38% of the company's stock.

Regulus Therapeutics Stock Up 3.7 %

NASDAQ RGLS traded up $0.06 on Wednesday, reaching $1.70. The company had a trading volume of 540,163 shares, compared to its average volume of 1,179,711. Regulus Therapeutics Inc. has a 52 week low of $1.08 and a 52 week high of $3.79. The stock's 50 day moving average is $1.53 and its 200-day moving average is $1.72. The stock has a market cap of $111.35 million, a price-to-earnings ratio of -1.59 and a beta of 1.61.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.03). As a group, analysts forecast that Regulus Therapeutics Inc. will post -0.88 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. StockNews.com upgraded Regulus Therapeutics to a "sell" rating in a research report on Tuesday, September 17th. Oppenheimer reissued an "outperform" rating and set a $7.00 price objective on shares of Regulus Therapeutics in a report on Wednesday, August 14th. Finally, HC Wainwright restated a "buy" rating and set a $10.00 target price on shares of Regulus Therapeutics in a research report on Monday, November 11th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $10.80.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.